NEW YORK--(BUSINESS WIRE)--
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Meridian Bioscience, Inc. (NASDAQ:VIVO) resulting from allegations that Meridian may have issued materially misleading business information to the investing public.
On January 25, 2017, Meridian announced negative first-quarter 2017 fiscal year (“1Q 2017”) financial results, revised its previously issued revenue guidance for the 2017 fiscal year downwards, and announced that the Board of Directors reduced the annual indicated dividend rate. Chief Executive Officer of Meridian, John A. Kraeutler, attributed the negative 1Q 2017 results to revenue declines in Meridian’s Americas diagnostic business—Meridian’s largest profit driver—across all major product categories, “due to customer buying patterns and general weakness overall.” On this news, shares of Meridian fell sharply during intraday trading on January 25, 2017.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Meridian investors. If you purchased shares of Meridian before January 24, 2017 please visit the firm’s website at http://www.rosenlegal.com/cases-1036.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170125006192/en/
